OXERVATE® is a recombinant human nerve growth factor indicated for the treatment of neurotrophic keratitis (NK).

Prescribing Information

CONNECT to Care

 

Dompé CONNECT to Care

Access support and more from Prescription to Delivery

Dompé CONNECT to Care logo

Providing practices and patients with assistance every step of the way

Benefits verification

Prior authorizations

Patient financial assistance

Pharmacist consultation

Delivery coordination
& confirmation

General questions

Since approval in 2018, more than 2000 total ophthalmologists and optometrists have prescribed OXERVATE®1

Patient Enrollment

How to start a patient on OXERVATE®

A

Submit a Patient Enrollment Form

Remember: Patient Authorization section of enrollment form must be completed.

A completed enrollment form serves as the OXERVATE® prescription and enrolls the patient into Dompé CONNECT to Care.

DOWNLOAD FORM
OR

B

e-Prescribe and obtain patient consent

e-Prescribe to only 1 pharmacy:

CoAssist Pharmacy
NCPDP: 5733604   Phone: 1-855-382-2533

OR

Accredo Specialty Pharmacy
NCPDP: 4436920  Phone: 1-877-831-8112

Remember: Submit a Patient Authorization Form to provide patient consent.

Questions? Contact Dompé CONNECT to Care

Phone 1-877-422-4412
Fax 1-855-263-1775

With Dompé copay support, patients with commercial insurance may pay as little as $0 out-of-pocket for an 8-week course of therapy

Sign up for additional resources and to stay up to date about OXERVATE®

For US healthcare professionals only.

Important Safety Information

WARNINGS AND PRECAUTIONS

Use with Contact Lens

Contact lenses should be removed before applying OXERVATE because the presence of a contact lens (either therapeutic or corrective) could theoretically limit the distribution of cenegermin-bkbj onto the area of the corneal lesion. Lenses may be reinserted 15 minutes after administration.

Eye Discomfort

OXERVATE may cause mild to moderate eye discomfort such as eye pain during treatment. The patient should be advised to contact their doctor if a more serious eye reaction occurs.

ADVERSE REACTIONS

In clinical trials, the most common adverse reaction was eye pain following instillation which was reported in approximately 16% of patients. Eye pain may arise as corneal healing occurs. Other adverse reactions occurring in 1% to 10% of OXERVATE patients included corneal deposits, foreign body sensation, ocular hyperemia, ocular inflammation, photophobia, tearing, and headache.

USE IN SPECIFIC POPULATIONS

Pregnancy

There are no data from the use of OXERVATE in pregnant women to inform any drug associated risks.

Lactation

The developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for OXERVATE, and any potential adverse effects on the breastfed infant from OXERVATE.

Pediatric Use

The safety and effectiveness of OXERVATE have been established in the pediatric population. Use of OXERVATE in pediatric patients 2 years of age and older is supported by evidence from adequate and well- controlled trials of OXERVATE in adults with additional safety data in children.

INDICATION

OXERVATE® (cenegermin-bkbj) ophthalmic solution 0.002% (20 mcg/mL) is indicated for the treatment of neurotrophic keratitis.

DOSAGE AND ADMINISTRATION

Instill one drop of OXERVATE in the affected eye(s), 6 times a day at 2-hour intervals for eight weeks.

To report ADVERSE REACTIONS, contact Dompé U.S. Inc. at 1‌-‌8‌3‌3‌-‌3‌6‌6‌-‌7‌3‌8‌7 or FDA at 1‌-‌8‌0‌0‌-‌F‌D‌A‌-‌1‌0‌8‌8 or www.fda.gov/medwatch.

Please see full Prescribing Information for OXERVATE.

References: 1. Data on File. Dompé Hub Data (REF-01027). Dompé U.S. Inc.; 2025. 2. Data on File. Pharmacy Adjudicated Claims Report (REF-01024). Dompé U.S. Inc.; 2025.